Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Tayshia Jean Therapy's full-year 2025 Financial Results Conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Haley Collins, Senior Director of Corporate Communications and Investor Relations. Please go ahead. Thank you. Good morning and welcome to Tayshia's full year 2025 financial results and corporate update conference call. Earlier today, Tayshia issued a press release announcing financial results for the full year ended December 31st, 2025. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Tayshia's Chief Executive Officer, Sukumar Nagandran, President and Head of R&D, and Cameron Alam, Chief Financial Officer. We will hold a question and answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including statements concerning the potential of Tayshia-102, including the reproducibility and durability of any favorable results initially seen in patients' dose-to-date and clinical trials. including with respect to functional milestones to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development, and regulatory plans for our product candidates, including the timing of i...